Literature DB >> 19527447

Obesity, the PI3K/Akt signal pathway and colon cancer.

X-F Huang1, J-Z Chen.   

Abstract

Obesity is currently reaching epidemic levels worldwide and is a major predisposing factor for a variety of life-threatening diseases including diabetes, hypertension and cardiovascular diseases. Recently, it has also been suggested to be linked with cancer. Epidemiological studies have shown that obesity increases the risk of colon cancer by 1.5-2 fold with obesity-associated colon cancer accounting for 14-35% of total incidence. Several factors, altered in obesity, may be important in cancer development including increased levels of blood insulin, insulin-like growth factor I, leptin, TNF-alpha, IL-6 as well as decreased adiponectin. A unifying characteristic of all these factors is that they increase the activity of the PI3K/Akt signal pathway. The PI3K/Akt signal pathway in turn activates signals for cell survival, cell growth and cell cycle leading to carcinogenesis. Here we review the evidence that PI3K/Akt and its downstream targets are important in obesity-associated colon cancer and thus, that targeted inhibition of this pathway could be employed for the prevention of obesity-associated colon cancer and incorporated into the therapy regime for those with irremovable colon cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527447     DOI: 10.1111/j.1467-789X.2009.00607.x

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  75 in total

1.  Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk.

Authors:  Mathilde Touvier; Léopold Fezeu; Namanjeet Ahluwalia; Chantal Julia; Nathalie Charnaux; Angela Sutton; Caroline Méjean; Paule Latino-Martel; Serge Hercberg; Pilar Galan; Sébastien Czernichow
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

2.  Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells.

Authors:  Daniel Prabakaran; Baogui Wang; Joseph D Feuerstein; Jennifer A Sinclair; Priti Bijpuria; Lisa I Jepeal; M Michael Wolfe
Journal:  Regul Pept       Date:  2010-04-28

Review 3.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

4.  Comment on "effects of adipocyte-secreted factors on cell cycle progression in HT29 cells" published by Eur J Nutr.

Authors:  Jiezhong Chen; Xu-Feng Huang
Journal:  Eur J Nutr       Date:  2009-12       Impact factor: 5.614

5.  Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.

Authors:  Wei-Dong Yu; Yi-Fan Peng; Hong-Da Pan; Lin Wang; Kun Li; Jin Gu
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

6.  Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29.

Authors:  Jiezhong Chen; Xu-Feng Huang; Liang Qiao; Andrew Katsifis
Journal:  J Gastrointest Oncol       Date:  2011-03

7.  Risk Factor Profiles Differ for Cancers of Different Regions of the Colorectum.

Authors:  Liang Wang; Chun-Han Lo; Xiaosheng He; Dong Hang; Molin Wang; Kana Wu; Andrew T Chan; Shuji Ogino; Edward L Giovannucci; Mingyang Song
Journal:  Gastroenterology       Date:  2020-04-01       Impact factor: 22.682

Review 8.  Obesity and cancer--mechanisms underlying tumour progression and recurrence.

Authors:  Jiyoung Park; Thomas S Morley; Min Kim; Deborah J Clegg; Philipp E Scherer
Journal:  Nat Rev Endocrinol       Date:  2014-06-17       Impact factor: 43.330

9.  Combined randomised controlled trial experience of malignancies in studies using insulin glargine.

Authors:  P D Home; P Lagarenne
Journal:  Diabetologia       Date:  2009-09-15       Impact factor: 10.122

10.  An updated meta-analysis of the association between ADIPOQ rs2241766 polymorphism and colorectal cancer.

Authors:  Peng Li; Hongyi Liu; Chen Li; Bo Yang; Qinglong Kong; Wei Zheng; Bing Li; Baoqing Jia
Journal:  Tumour Biol       Date:  2013-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.